U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib) as First Broad RAS-Targeted Medicine for Metastatic Pancreatic Cancer

August 30, 2026

MarketScreener USA

Overview

Revolution Medicines announced that its RASONQUE™ (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer, has received U.S. FDA approval. RASONQUE had previously been granted Breakthrough Therapy designation and Orphan Drug designation for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) patients. This approval brings new hope to patients with this difficult-to-treat disease, where therapeutic options have been limited, and its broad RAS targeting potential could benefit a wider patient population.

In Depth

Key Findings

Revolution Medicines announced that the U.S. Food and Drug Administration (FDA) has approved its drug, RASONQUE™ (generic name: daraxonrasib), as the first broad RAS-targeted medicine for metastatic pancreatic cancer. This approval is for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and follows the drug’s prior designations as a Breakthrough Therapy and an Orphan Drug. For patients with metastatic pancreatic cancer, a condition with extremely limited treatment options, this represents a groundbreaking advancement.

Technical / Clinical Details

RASONQUE (daraxonrasib) is an innovative molecularly targeted therapy that broadly targets the RAS pathway. RAS gene mutations are frequently observed driver mutations in many cancer types, including pancreatic cancer, and have historically been considered difficult targets for therapy. RASONQUE possesses a mechanism that inhibits the proliferation of cancer cells not only with specific RAS mutations but also with diverse RAS variant types. In clinical trials, the drug demonstrated promising results in metastatic PDAC patients, including tumor shrinkage and disease stabilization, even in cases resistant to existing treatments. Its safety profile is manageable, and it is expected to improve the quality of life (QOL) compared to conventional chemotherapy.

Background & Context

Pancreatic cancer is one of the deadliest cancers, with the 5-year survival rate for metastatic pancreatic cancer remaining in single digits. Its treatment has been a significant challenge for many years due to limited therapeutic options and issues of drug resistance. The development of RAS-targeted drugs has been a long-standing goal in cancer treatment, but success stories have been extremely rare due to the pathway’s complexity. RASONQUE’s approval, particularly its broad RAS targeting, represents a major breakthrough in this challenging field and symbolizes the advancement of precision medicine.

Strategic Significance & Outlook

RASONQUE’s FDA approval brings new hope to patients with metastatic pancreatic cancer and is expected to significantly impact clinical practice guidelines. This drug is likely to be integrated into the standard of care for this disease, which has an exceptionally high unmet medical need. Furthermore, the success of a broad RAS-targeting approach is anticipated to catalyze the development of similar therapies for other cancer types (e.g., lung cancer, colorectal cancer) where RAS mutations are involved. For Revolution Medicines, this approval will dramatically increase its corporate value and positively impact its entire oncology pipeline.

Source: https://www.marketscreener.com/news/u-s-fda-approves-revolution-medicinesa-rasonquea-daraxonrasib-the-first-broad-ras-targeted-m-ce7858d9df80f227

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.